Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Treatment, Healthcare Utilization And Outcomes In Patients With Glioblastoma In Ontario: A 10-year Cohort Study.
  1. Home
  3. Treatment, Healthcare Utilization And Outcomes In Patients With Glioblastoma In Ontario: A 10-year Cohort Study.

Related Concept Videos

Related Experiment Video

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
09:10

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

Published on: November 15, 2024

396

Treatment, healthcare utilization and outcomes in patients with glioblastoma in Ontario: a 10-year cohort study.

Wafa Baqri1, Kathryn Rzadki2, Steven Habbous3,4

  • 1Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.

Journal of Neuro-Oncology
|May 3, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Glioblastoma survival remains stable, but adjuvant chemoradiation increased, especially for older patients. Regionalization improved access to care, benefiting elderly glioblastoma patients.

Keywords:
GlioblastomaHealthcare utilizationSurvivalTreatment

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Related Experiment Videos

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma
09:10

An Immunocompetent Murine Model for Laser Interstitial Thermal Therapy of Glioblastoma

Published on: November 15, 2024

396
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

18.0K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Area of Science:

  • Neuro-oncology
  • Public Health
  • Health Services Research

Background:

  • Glioblastoma (GBM) is the most common aggressive primary brain tumor in adults.
  • Adjuvant therapies significantly improve glioblastoma patient survival.
  • Real-world outcomes are influenced by evolving care standards and healthcare system factors like access.

Purpose of the Study:

  • To examine GBM care in Ontario from 2010-2019.
  • To analyze treatment patterns, healthcare utilization, and survival.
  • To interpret the impact of practice changes and network expansion on glioblastoma outcomes.

Main Methods:

  • Population-based cohort study using linked health-administrative databases in Ontario, Canada.
  • Examined clinical characteristics, treatment, and healthcare utilization of adult GBM patients (2010-2019).
  • Primary outcomes: adjuvant chemoradiation enrollment and 1-, 2-, and 5-year survival rates.

Main Results:

  • 5392 GBM patients diagnosed (2010-2019); 58% male, median age 64.
  • Adjuvant chemoradiation increased from 51% (2010) to 63% (2019).
  • Overall survival remained stable (1-year: 40-43%, 2-year: 15-19%, 5-year: 5-7%); however, 1-year survival for patients >65 increased from 19% to 26%.

Conclusions:

  • Regionalization improved treatment accessibility closer to patients' homes.
  • Increased adjuvant chemoradiation in elderly patients was observed.
  • Improved 1-year survival in older GBM patients was linked to sociodemographic and clinical factors, supporting regionalization efforts.